MBIO — MindBio Therapeutics Cashflow Statement
0.000.00%
- CA$6.75m
- CA$8.72m
Annual cashflow statement for MindBio Therapeutics, fiscal year end - June 30th, AUD millions except per share, conversion factor applied.
2021 June 30th | 2022 June 30th | 2023 June 30th | 2024 June 30th | 2025 June 30th | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | PROSPECTUS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -0.477 | -7.51 | -4.29 | -0.407 | -2.81 |
| Non-Cash Items | 0 | 1.96 | 2.36 | 0.196 | 1.71 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 0.477 | 0.823 | -0.289 | -0.173 | 0.599 |
| Change in Accounts Receivable | |||||
| Change in Payable / Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | 0 | -4.72 | -2.21 | -0.383 | -0.494 |
| Other Investing Cash Flow Items | 0 | -0.033 | 0 | — | 0.01 |
| Sale of Business | |||||
| Purchase of Investments | |||||
| Cash from Investing Activities | 0 | -0.033 | 0 | — | 0.01 |
| Financing Cash Flow Items | — | — | — | 0.285 | -0 |
| Other Financing Cash Flow | |||||
| Total Cash Dividends Paid | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 0.48 | 5.59 | 1.04 | 0.272 | 0.431 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 0.48 | 0.835 | -0.996 | -0.18 | -0.075 |